If you are interested in more information about a particular trial, please talk with your treating physician first, and they may contact this centre for further information if necessary.
|
Tumour Group / Site |
Trial Title |
Opening Date |
|---|
BREAST
| A Randomized Phase III Trial To Evaluate the Efficacy and Safety of Mk-3475 (Pembrolizumab) as Adjuvant Therapy For Triple Receptor-Negative Breast Cancer With ≥ 1 cm Residual Invasive Cancer or Positive Lymph Nodes (Ypn+) After Neoadjuvant Chemotherapy
(CCTG MAC.24)
| Nov 2019
|
| BREAST | A Randomized Trial of Regional Radiotherapy In Biomarker Low Risk Node Positive Breast Cancer (CCTG MA.39) | Sept 2019
|
BREAST
| A Phase III, Multicenter, Randomized, Open-Label Trial To Evaluate Efficacy And Safety Of Ribociclib With Endocrine Therapy As An Adjuvant Treatment In Patients With Hormone Receptor-Positive, HER2-Negative, Early Breast Cancer (NATALEE)
| Jun
2019
|
BREAST
| A Phase III, Double-Blind, Placebo-Controlled, Randomized Study of Ipatasertib in Combination with Atezolizumab and Paclitaxel as a Treatment for Patients with Locally Advanced Unresectable or Metastatic Triple-Negative Breast Cancer (IPAT)
| March 2020
|
GYNE
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA) | Feb 2019
|
|
|
|
| Lung | A Phase II/III Randomized Study of Pembrolizumab in Patients with Advanced Malignant Pleural
Mesothelioma (CCTG IND.227)
| Feb 2017 |
|
Lymphoma | Biology of Lymphoid Cancer
(Lymphoid Study) | Jan 2014 |
| Melanoma | A Randomized Phase III Study of Duration of Anti-PD-1 Therapy in Metastatic Melanoma (STOP-GAP) CCTG ME.13 | July 2017
|
You can view a video on participating in clinical trials that was created by staff at BC Cancer's Fraser Valley Centre.
http://learn.phsa.ca/bcca/clinicaltrials/2012oct23/ClinicalTrials2012oct23_flv_loader.html
|
